Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 May 2017 12:01

RNS Number : 9800F
Advanced Oncotherapy PLC
23 May 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Advanced Oncotherapy plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights :

Other (please specify):

CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE

 

 

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Available on Request 7,068*

 

Chase (GA Group) Nominees Limited 1,950,852*

 

HSBC Global Custody Nominee (UK) Limited 328,573*

*denotes direct interest

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

19 May 2017

6. Date on which issuer notified:

22 May 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

3% to

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares GBP 0.25GB00BD6SX109

2,296,493 *

2,296,493 *

2,286,493

2,286,493

** Not disclosable

2.98%

** Not disclosable

 

* Includes Right to Recall Loaned Shares (10,000)

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

 

N/A

N/A

10,000*

 

*Direct Interest

0.01%

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,296,493

2.99%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited and Friends Provident International Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

 

13. Additional information:

Figures are based on a total number of voting rights of 76,609,194 as per the Company's 'Conversion of Convertible Loan Notes' announcement of

16 May 2017.

 

** Although not reportable, as per DTR5.1.5,the non-disclosable (indirect) position is currently 865,438 shares, and is included here in the interests of transparency.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOVRRBOAVUAR
Date   Source Headline
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.